<DOC>
	<DOCNO>NCT01450995</DOCNO>
	<brief_summary>This open label , 6 month cross study 50 migraine patient fulfil International Headache Society Classification criterion migraine headache without aura 2-6 migraine per month 14 day month headache previous 3 month . Baseline Headache Impact Test -6 ( HIT-6 ) obtain 25 patient administer Treximet need 3 month 2 Aleve 100mg Imitrex take concomitantly need 3 month . The 25 patient administer 2 Aleve 100mg Imitrex take concomitantly need 3 month Treximet need 3 month . In addition Revised Patient Perception Migraine Questionnaire ( PPMQ-R ) data , detailed diary record regard number tablet take per attack , compliance , rescue treatment , patient treat migraine attack ( mild , moderate , severe ) , onset pain reduction ( pain relief pain free , 24 hour pain relief sustain pain free response .</brief_summary>
	<brief_title>Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve Imitrex</brief_title>
	<detailed_description>A migraine headache characterize pain felt one sometimes side ( ) head . Other symptom associate migraine headache may include nausea , vomit , sensitivity light sound . A migraine last hour one two day . Triptan medication currently think safe effective acute migraine treatment . Treximet ( tm ) triptan tablet contain combination sumatriptan 85mg ( Imitrex ) naproxen sodium 500 mg . This combination two method action relieve migraine headache . It target nerve blood vessel involve migraine , relieve inflammation may cause migraine pain . Treximet ( tm ) , approve Food Drug Administration . The purpose research study compare effectiveness take Treximet ( tm ) combination pill take two Aleve ( r ) tablets 100mg Imitrex ( r ) separate tablet take time .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : 1 . Subject male female . 2 . Subject age 18 65 . 3 . A female eligible enter participate study breast feeding : nonchildbearing potential ( i.e . physiologically incapable become pregnant ) childbearing potential , negative urine pregnancy test screening agree use acceptable method contraception course study , Female sterilization ; , Sterilization male partner ; Implants levonorgestrel ; Injectable progestogen ; Oral contraceptive ( combine progestogen ) ; Any intrauterine device ( IUD ) meet criterion ; Double barrier method ; Any method publish data show low expected failure rate method le 1 % per year 4 . Subject diagnosis migraine meet IHS criterion migraine without aura ( 1.1 ) migraine aura ( 1.2 ) 5 . Subject least 1year history migraine 26 migraine per month three month prior screen 6 . Subject typically experience moderate severe migraine pain precede identifiable mild pain phase . 7 . Subject able read , understand complete diary , subject questionnaire instruction study . 8 . Subject able willing give write informed consent participate study . A subject eligible inclusion study follow criterion apply : 1 . Subject confirm suspected ischemic heart disease ( angina pectoris , history myocardial infarction , document silent ischemia ) , Prinzmetal 's angina , signs/symptoms consistent . 2 . Subject evidence history ischemic abdominal syndrome , peripheral vascular disease Raynaud 's Syndrome . 3 . Subject cardiac arrhythmia require medication clinically significant electrocardiogram abnormality , investigator 's opinion , contraindicate participation study . 4 . Subject history cerebrovascular pathology include stroke . 5 . Subject history congenital heart disease . 6 . Subject uncontrolled hypertension screening ( sit ( &gt; 140 mmHg systolic pressure &gt; 90mmHg diastolic pressure ) . 7 . Subject , investigator 's opinion , likely unrecognized cardiovascular cerebrovascular disease . 8 . Subject significant peripheral vascular disease 9 . Subject currently take anticoagulant ( e.g. , Coumadin® ) . 10 . Subject history inflammatory bowel disease . 11 . Subject history bleeding disorder . 12 . Subject history GI ulceration past six month gastrointestinal bleeding past year . 13 . Subject take antiplatelet agent ( except lowdose aspire ≤ 325 mg/day cardioprotective reason ) . 14 . Subject take angiotensinconverting enzyme ( ACE ) inhibitor angiotensin receptor blocker . 15 . Subject history epilepsy . 16 . Subject basilar migraine , hemiplegic migraine cluster headache . 17 . Subject impaired renal , hepatic , gastrointestinal surgery , gastrointestinal obstruction perforation . 18 . Subject currently take monoamine oxidase inhibitor drug ( MAOIs ) , take MAOI within 2 week prior screen . 19 . Subject pregnant , actively try become pregnant breastfeeding . 20 . Subject ≥ 15 headache day three previous month prior screen . 21 . Subject childbearing potential use adequate contraceptive measure . 22 . Subject evidence rebound headache pattern cause ergotamine analgesic past three month . 23 . Subject evidence alcohol substance abuse within last year , , investigator 's judgment , likely interfere study conduct , subject cooperation , evaluation interpretation study result . 24 . Subject concurrent medical condition may affect interpretation efficacy safety data otherwise contraindicate participation clinical trial . 25 . Subject participate investigational drug trial within previous four week , plan participate another study time study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Headache , Migraine</keyword>
</DOC>